BIRC5 and ovarian carcinoma: When ovarian cancer cells were treated with these chemotherapeutic agents (cisplatin and paclitaxel) in the absence and presence of YM155, their viability was more effectively reduced in the presence of YM155, suggesting that pharmacological inhibition of survivin expression enhanced the growth inhibitory effects of cisplatin and paclitaxel (Figure 7a,b).